Insider Purchases: Inside the Buy
Tag: Biotech Investing
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?
Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?
Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?
Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?
🏰 KKR: Kingdom of Capital and... Real Estate, Biotech, Semiconductors, Grocery Stores, and Also Probably Your Mom’s Soup Recipe?
KKR isn’t just a firm—it’s a capital empire. And when several directors shell out millions of dollars for shares, you take notice. From fee-rich earnings to a stake in just about everything that breathes profit, here's why KKR might deserve a seat in your portfolio—and your heart. 💼❤️ Director Robert Scully just bought big into KKR—and he’s not alone. With $664B in assets under management and a deal machine that never sleeps, KKR might just be the king of kings in capital. Here's our fun (and slightly ridiculous) take on whether it deserves a spot in your portfolio.